{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:59:15Z","timestamp":1785495555774,"version":"3.56.0"},"reference-count":142,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>In metastatic prostate cancer, there have been pronounced survival gains driven by the introduction of combination and intensification strategies. Consequently, many patients now experience prolonged survival with metastatic disease. While these advances represent a major therapeutic success, prolonged exposure to systemic therapies is associated with a broad spectrum of adverse effects. These side effects affect multiple domains, including bone health, cardiovascular risk, physical function, and psychological well-being. As a result, survivorship has emerged as a critical and increasingly relevant aspect of care in metastatic prostate cancer. In parallel, the importance of patient-reported outcomes in clinical trials, alongside traditional oncologic endpoints, is increasingly acknowledged. Overall, survivorship care in metastatic disease remains incompletely conceptualized as the long-term impact of cumulative treatment burden is often underrecognized. This narrative review examines key survivorship challenges in metastatic prostate cancer in an era of improving survival, with a focus on treatment-related toxicities, quality of life, and unmet needs in supportive care. We highlight current evidence, identify gaps in knowledge, and discuss future directions for integrating survivorship into routine clinical practice.<\/jats:p>","DOI":"10.3390\/cancers18152465","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:11:38Z","timestamp":1785492698000},"page":"2465","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survivorship Challenges in Metastatic Prostate Cancer in the Era of Prolonged Survival: A Review"],"prefix":"10.3390","volume":"18","author":[{"given":"Cristina","family":"Cano Garcia","sequence":"first","affiliation":[{"name":"Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON L8L 2X2, Canada"},{"name":"Department of Surgery, McMaster University, Hamilton, ON L8S 4K1, Canada"},{"name":"Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, 60596 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Moryousef","sequence":"additional","affiliation":[{"name":"Department of Surgery, McMaster University, Hamilton, ON L8S 4K1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehonathan H.","family":"Pinthus","sequence":"additional","affiliation":[{"name":"Department of Surgery, McMaster University, Hamilton, ON L8S 4K1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl P.","family":"Leong","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON L8L 2X2, Canada"},{"name":"Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, ON L8N 3Z5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"Bethesda, M. (2026, May 04). SEER Cancer Stat Facts: Prostate Cancer. National Cancer Institute, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0140-6736(25)02221-4","article-title":"Prostate Cancer","volume":"407","author":"Fonteyne","year":"2026","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of Androgen Deprivation Therapy with Cardiovascular Death in Patients with Prostate Cancer A Meta-Analysis of Randomized Trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.annonc.2025.08.004","article-title":"Ten-Year Survival Rates by PSA Nadir in Patients with Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis from the ECOG-ACRIN 3805 (CHAARTED) Trial","volume":"36","author":"Tripathi","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of Docetaxel to Hormonal Therapy in Low- And High-Burden Metastatic Hormone Sensitive Prostate Cancer: Long-Term Survival Results from the STAMPEDE Trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone Acetate plus Prednisone in Patients with Newly Diagnosed High-Risk Metastatic Castration-Sensitive Prostate Cancer (LATITUDE): Final Overall Survival Analysis of a Randomised, Double-Blind, Phase 3 Trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone Acetate plus Prednisolone with or without Enzalutamide for Patients with Metastatic Prostate Cancer Starting Androgen Deprivation Therapy: Final Results from Two Randomised Phase 3 Trials of the STAMPEDE Platform Protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone Suppression plus Enzalutamide versus Testosterone Suppression plus Standard Antiandrogen Therapy for Metastatic Hormone-Sensitive Prostate Cancer (ENZAMET): An International, Open-Label, Randomised, Phase 3 Trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.eururo.2025.12.021","article-title":"ARCHES 5-Year Survival with Enzalutamide Plus Androgen-Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer Patients","volume":"89","author":"Armstrong","year":"2026","journal-title":"Eur. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved Survival with Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study","volume":"39","author":"Chi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in Combination with Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer from the Phase III ARANOTE Trial","volume":"42","author":"Saad","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus Prednisone Added to Androgen Deprivation Therapy and Docetaxel in de Novo Metastatic Castration-Sensitive Prostate Cancer (PEACE-1): A Multicentre, Open-Label, Randomised, Phase 3 Study with a 2 \u00d7 2 Factorial Design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate Cancer: A Review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy with Enzalutamide or Placebo in Men with Metastatic Hormone-Sensitive Prostate Cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate Radiotherapy for Metastatic Hormone-Sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-Analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT Alone for Hormone-Sensitive Oligorecurrent Prostate Cancer (RADIOSA): A Randomised, Open-Label, Phase 2 Clinical Trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage Metastasis-Directed Therapy versus Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases (PEACE V\u2013STORM): A Phase 2, Open-Label, Randomised Controlled Trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer","volume":"381","author":"Sternberg","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.annonc.2025.07.003","article-title":"Final Overall Survival and Safety Analyses of the Phase III PSMAfore Trial of [177Lu]Lu-PSMA-617 versus Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer","volume":"36","author":"Fizazi","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or Physician\u2019s Choice in Metastatic Prostate Cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus Abiraterone versus Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-Blind, Phase 3 Trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Results from the Randomised, Placebo-Controlled, Phase 3 TALAPRO-2 Trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.euo.2025.04.012","article-title":"Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial","volume":"8","author":"Chi","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.annonc.2026.02.009","article-title":"Final Overall Survival Results from EORTC 1333\/PEACE-3 Trial of Enzalutamide plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Gillessen","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus Enzalutamide in Men with First-Line Metastatic Castration-Resistant Prostate Cancer (TALAPRO-2): A Randomised, Placebo-Controlled, Phase 3 Trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus Abiraterone Acetate with Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations: Second Interim Analysis of the Randomized Phase III MAGNITUDE Trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.annonc.2025.05.011","article-title":"Enzalutamide plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Results of the EORTC 1333\/PEACE-3 Trial","volume":"36","author":"Tombal","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2014.60.2557","article-title":"Prostate Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement","volume":"33","author":"Resnick","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/JU.0000000000004359","article-title":"A Tailored Electronic Survivorship Care Plan for Prostate Cancer Survivors: A Multicenter Randomized Controlled Trial","volume":"213","author":"Jones","year":"2025","journal-title":"J. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/OP.23.00716","article-title":"Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations","volume":"20","author":"Hart","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"ref_46","unstructured":"Peterson, L.L., McDonough, A.L., Ansbaugh, S.M., Ella Ariza-Heredia, P.J., Scott Baker, K., Ballinger, T.J., Cathcart-Rake, E.J., Cohen, S.H., \u0152, L., and Day, A.T. (2026, July 22). NCCN Guidelines Version 2.2026 Survivorship. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1466."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Spratt, D.E., An, Y., Bitting, R., Chapin, B., Cheng, H.H., Cho, S.Y., D\u2019Amico, A.V., Desai, N., Dorff, T., and Eastham, J.A. (2026, July 22). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Prostate Cancer. Version 5. Available online: https:\/\/education.nccn.org\/May2026#group-tabs-node-course-default1.","DOI":"10.6004\/jnccn.2026.0023"},{"key":"ref_48","unstructured":"Cornford, P., Tilki, D., van den Bergh, R.C.N., Eberli, D., Fonteyne, V., Gandaglia, G., Gillessen, S., Henry, A.M., and van Leenders, G.J.L.H. (2026). Guidelines on Prostate Cancer, European Association of Urology."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1200\/JCO-25-02834","article-title":"Trial Design and Objectives for Patients with Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4","volume":"44","author":"Armstrong","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-5347(05)00033-9","article-title":"Risk of Clinical Fractures after Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer","volume":"175","author":"Smith","year":"2006","journal-title":"J. Urol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pds.2258","article-title":"Timing of Androgen Deprivation Therapy Use and Fracture Risk among Elderly Men with Prostate Cancer in the United States","volume":"21","author":"Cetin","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus Zoledronic Acid for Treatment of Bone Metastases in Men with Castration-Resistant Prostate Cancer: A Randomised, Double-Blind Study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-Resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.eururo.2024.11.027","article-title":"Decrease in Fracture Rate with Mandatory Bone-Protecting Agents in the EORTC 1333\/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1200\/JCO-25-02835","article-title":"Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men with Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)","volume":"44","author":"McKay","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2025.43.5_suppl.163","article-title":"Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer (MCRPC) Treated with Denosumab in a Randomized Phase III Trial Comparing 4 vs. 12 Weekly Administration (REDUSE, SAKK 96\/12)","volume":"43","author":"Templeton","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41391-022-00573-y","article-title":"Real-World Use of Bone Modifying Agents in Metastatic, Castration-Resistant Prostate Cancer","volume":"26","author":"Mitchell","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized Controlled Trial of Early Zoledronic Acid in Men with Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Saporita, I., Calabrese, M., Carfi, F.M., Mogavero, A., Puglisi, M., Treglia, G., Vogl, U.M., Gillessen, S., Pereira Mestre, R., and Pedrani, M. (2026). Risk of Bone Fractures in Patients with Prostate Cancer Treated with Maximal Androgen Blockade Therapy: A Systematic Literature Review and Meta-Analysis. Prostate Cancer Prostatic Dis.","DOI":"10.1038\/s41391-026-01077-9"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.annonc.2025.07.005","article-title":"Fracture-Related Hospitalisations in Newly Diagnosed High-Risk Localised or Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of the STAMPEDE Phase III Trials of Docetaxel and Zoledronic Acid Using Healthcare Systems Data","volume":"36","author":"Jones","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e242467","DOI":"10.1001\/jamanetworkopen.2024.2467","article-title":"Bone-Modifying Agents in Patients with High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated with Abiraterone Acetate","volume":"7","author":"Fukuokaya","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"117906","DOI":"10.1016\/j.bone.2026.117906","article-title":"Multiparametric Assessment of Bone Health in Metastatic Hormone-Sensitive Prostate Cancer Patients Receiving Androgen Deprivation + Enzalutamide \u00b1 Zoledronic Acid (BonEnza Study)","volume":"209","author":"Caramella","year":"2026","journal-title":"Bone"},{"key":"ref_63","first-page":"116","article-title":"Addition of Zoledronic Acid to Enzalutamide and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: The Randomized Phase II BONENZA Trial","volume":"29","author":"Valcamonico","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41391-024-00897-x","article-title":"Comprehensive Review of Cardiovascular Disease in Prostate Cancer: Epidemiology, Risk Factors, Therapeutics and Prevention Strategies","volume":"28","author":"Moryousef","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and Cardiovascular Disease during Androgen Deprivation Therapy: Observational Study of Veterans with Prostate Cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-Analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and Timing of Cardiovascular Disease after Androgen-Deprivation Therapy in Men with Prostate Cancer","volume":"33","author":"Garmo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Zhao, J., Zhu, S., Sun, L., Meng, F., Zhao, L., Zhao, Y., Tian, H., Li, P., and Niu, Y. (2014). Androgen Deprivation Therapy for Prostate Cancer Is Associated with Cardiovascular Morbidity and Mortality: A Meta-Analysis of Population-Based Observational Studies. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107516"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e2119568","DOI":"10.1001\/jamanetworkopen.2021.19568","article-title":"Causes of Death among Patients with Metastatic Prostate Cancer in the US from 2000 to 2016","volume":"4","author":"Elmehrath","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_70","first-page":"44","article-title":"Rationale and Design of RADICAL PC: A Trial of Cardioprotective Strategies in Prostate Cancer","volume":"4","author":"Leong","year":"2026","journal-title":"JU Open Plus"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/JU.0000000000000714","article-title":"Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study","volume":"203","author":"Leong","year":"2020","journal-title":"J. Urol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaccao.2022.09.008","article-title":"The Burden of Uncontrolled Cardiovascular Risk Factors in Men with Prostate Cancer: A RADICAL-PC Analysis","volume":"5","author":"Klimis","year":"2023","journal-title":"JACC CardioOncol"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular Safety of Degarelix Versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"key":"ref_74","first-page":"303","article-title":"Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer","volume":"205","author":"Shore","year":"2021","journal-title":"J. Urol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jaccao.2023.05.011","article-title":"Cardiovascular Effects of GnRH Antagonists Compared with Agonists in Prostate Cancer: A Systematic Review","volume":"5","author":"Nelson","year":"2023","journal-title":"JACC CardioOncol"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamacardio.2025.5586","article-title":"Coronary Plaque Progression After Androgen Deprivation Therapy in Men with Prostate Cancer: A Randomized Clinical Trial","volume":"11","author":"Patel","year":"2026","journal-title":"JAMA Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/ehjcvp\/pvab005","article-title":"The Cardiovascular Effects of Gonadotropin-Releasing Hormone Antagonists in Men with Prostate Cancer","volume":"8","author":"Cirne","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"10","author":"Taktak","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jaccao.2024.07.011","article-title":"Adiposity and Muscle Strength in Men with Prostate Cancer and Cardiovascular Outcomes","volume":"6","author":"Leong","year":"2024","journal-title":"JACC CardioOncol"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Newton, R.U., Taaffe, D.R., Spry, N., Cormie, P., Chambers, S.K., Gardiner, R.A., Shum, D.H.K., Joseph, D., and Galv\u00e3o, D.A. (2012). Can Exercise Ameliorate Treatment Toxicity during the Initial Phase of Testosterone Deprivation in Prostate Cancer Patients? Is This More Effective than Delayed Rehabilitation?. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-432"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1249\/MSS.0000000000001277","article-title":"Exercise Improves VO2max and Body Composition in Androgen Deprivation Therapy-Treated Prostate Cancer Patients","volume":"49","author":"Wall","year":"2017","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.euo.2024.09.012","article-title":"Immediate Versus Delayed Exercise on Health-Related Quality of Life in Patients Initiating Androgen Deprivation Therapy: Results from a Year-Long Randomised Trial","volume":"8","author":"Taaffe","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/bju.14505","article-title":"Immediate versus Delayed Exercise in Men Initiating Androgen Deprivation: Effects on Bone Density and Soft Tissue Composition","volume":"123","author":"Taaffe","year":"2019","journal-title":"BJU Int."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1249\/MSS.0000000000003095","article-title":"Resistance Exercise Training Increases Muscle Mass and Strength in Prostate Cancer Patients on Androgen Deprivation Therapy","volume":"55","author":"Houben","year":"2023","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Dawson, J.K., Dorff, T.B., Todd Schroeder, E., Lane, C.J., Gross, M.E., and Dieli-Conwright, C.M. (2018). Impact of Resistance Training on Body Composition and Metabolic Syndrome Variables during Androgen Deprivation Therapy for Prostate Cancer: A Pilot Randomized Controlled Trial. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4306-9"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/bjc.2015.479","article-title":"Effects of a Lifestyle Intervention on Endothelial Function in Men on Long-Term Androgen Deprivation Therapy for Prostate Cancer","volume":"114","author":"Gilbert","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Baguley, B.J., Adlard, K., Jenkins, D., Wright, O.R.L., and Skinner, T.L. (2022). Mediterranean Style Dietary Pattern with High Intensity Interval Training in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Pilot Randomised Control Trial. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19095709"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41391-022-00519-4","article-title":"A Randomized Controlled Trial Comparing Changes in Fitness with or without Supervised Exercise in Patients Initiated on Enzalutamide and Androgen Deprivation Therapy for Non-Metastatic Castration-Sensitive Prostate Cancer (EXTEND)","volume":"25","author":"Harrison","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_89","first-page":"9011","article-title":"Factors Predicting Gains in Moderate-to-Vigorous Physical Activity in Prostate Cancer Survivors on Androgen Deprivation Therapy","volume":"30","author":"Papadopoulos","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"101646","DOI":"10.1016\/j.jgo.2023.101646","article-title":"Home-Based versus Supervised Group Exercise in Men with Prostate Cancer on Androgen Deprivation Therapy: A Randomized Controlled Trial and Economic Analysis","volume":"15","author":"Alibhai","year":"2024","journal-title":"J. Geriatr. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40798-020-00288-1","article-title":"Androgen Deprivation in Prostate Cancer: Benefits of Home-Based Resistance Training","volume":"6","author":"Lam","year":"2020","journal-title":"Sports Med. Open"},{"key":"ref_92","first-page":"146.e1","article-title":"Quality of Life for Men with Metastatic Castrate-Resistant Prostate Cancer Participating in an Aerobic and Resistance Exercise Pilot Intervention","volume":"41","author":"Langlais","year":"2023","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e70084","DOI":"10.1111\/sms.70084","article-title":"Is Exercise During Androgen Deprivation Therapy Effective and Safe? A Randomized Controlled Trial","volume":"35","author":"Rantaniemi","year":"2025","journal-title":"Scand. J. Med. Sci. Sports"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13063-025-08937-0","article-title":"High-Intensity Resistance and Impact Training for Patients with Hormone-Sensitive Prostate Cancer and Bone Metastases\u2014Study Protocol of a Randomized Clinical Trial","volume":"26","author":"Ragle","year":"2025","journal-title":"Trials"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"107973","DOI":"10.1016\/j.cct.2025.107973","article-title":"Exercise to Enhance Cardiovascular Health among Black Men with Prostate Cancer with Androgen Deprivation Therapy (the POWER Trial): A Study Protocol","volume":"155","author":"Kang","year":"2025","journal-title":"Contemp. Clin. Trials"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13063-024-07989-y","article-title":"Supported Exercise TrAining for Men wIth Prostate CaNcer on Androgen Deprivation Therapy (STAMINA): Study Protocol for a Randomised Controlled Trial of the Clinical and Cost-Effectiveness of the STAMINA Lifestyle Intervention Compared with Optimised Usual Care, Including Internal Pilot and Parallel Process Evaluation","volume":"25","author":"McNaught","year":"2024","journal-title":"Trials"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral Semaglutide 50 Mg Taken Once per Day in Adults with Overweight or Obesity (OASIS 1): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as Compared with Semaglutide for the Treatment of Obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for Obesity Treatment and Diabetes Prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Davies","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2337\/dc24-0491","article-title":"Effect of Semaglutide on Regression and Progression of Glycemia in People with Overweight or Obesity but Without Diabetes in the SELECT Trial","volume":"47","author":"Kahn","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2025.12.003","article-title":"Incretin Mimetics in Cancer and Cardiovascular Disease","volume":"8","author":"Leong","year":"2026","journal-title":"JACC CardioOncol"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.eururo.2025.12.004","article-title":"Beyond Menopause: Ending the Inequality\u2014Why Men with Prostate Cancer Still Lack Therapies for Hot Flushes","volume":"89","author":"Pedrani","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/s41416-026-03375-4","article-title":"Self-Help Cognitive Behavioural Therapy for Hot Flushes and Night Sweats during Androgen Deprivation Therapy for Prostate Cancer: The MANCAN2 Randomized Controlled Trial","volume":"134","author":"Crabb","year":"2026","journal-title":"Br. J. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Qin, Z., Zang, Z., Yu, J., Lv, J., Li, N., Zhang, J., Yang, M., Kwong, J.S.W., Pang, R., and Wang, J. (2023). Acupuncture versus Sham Acupuncture and Usual Care for Antiandrogen-Induced Hot FLashes in Prostate Cancer (AVAIL): Study Protocol for a Randomized Clinical Trial. BMC Complement. Med. Ther., 23.","DOI":"10.1186\/s12906-023-04218-y"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"453","DOI":"10.31557\/APJCP.2026.27.2.453","article-title":"Targeting Side Effects Associated with Androgen Deprivation Therapy Using Melatonin: A Randomized Trial on Hot Flashes and Sexual Health in Prostate Cancer Patients","volume":"27","author":"Hosseini","year":"2026","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_108","first-page":"128","article-title":"Gabapentin for the Management of Hot Flashes in Prostate Cancer Survivors: A Longitudinal Continuation Study-NCCTG Trial N00CB","volume":"8","author":"Moraska","year":"2010","journal-title":"J. Support. Oncol."},{"key":"ref_109","unstructured":"(2026, May 19). Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients with Prostate Cancer. Identifier: NCT01533753, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01533753."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO-25-01486","article-title":"Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer","volume":"44","author":"Stish","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_111","unstructured":"(2026, June 24). Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy (Fezo-ADT), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06957691."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa2511781","article-title":"Transdermal Estradiol Patches in Locally Advanced Prostate Cancer","volume":"394","author":"Langley","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-Reported Outcomes Following Abiraterone Acetate plus Prednisone Added to Androgen Deprivation Therapy in Patients with Newly Diagnosed Metastatic Castration-Naive Prostate Cancer (LATITUDE): An International, Randomised Phase 3 Trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","article-title":"Health-Related Quality of Life after Apalutamide Treatment in Patients with Metastatic Castration-Sensitive Prostate Cancer (TITAN): A Randomised, Placebo-Controlled, Phase 3 Study","volume":"20","author":"Agarwal","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.eururo.2020.03.019","article-title":"Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-Related Quality of Life in Patients with Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-Controlled, Phase 3 Study","volume":"78","author":"Stenzl","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1470-2045(26)00014-8","article-title":"Pain and Health-Related Quality-of-Life Outcomes with Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer (ARANOTE): Secondary and Exploratory Analyses of a Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"27","author":"Morgans","year":"2026","journal-title":"Lancet Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/annonc\/mdw065","article-title":"Patient-Reported Quality-of-Life Analysis of Radium-223 Dichloride from the Phase III ALSYMPCA Study","volume":"27","author":"Nilsson","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-Related Quality of Life and Pain Outcomes with [177Lu]Lu-PSMA-617 plus Standard of Care versus Standard of Care in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION): A Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(22)00017-1","article-title":"Pain and Health-Related Quality of Life with Olaparib versus Physician\u2019s Choice of next-Generation Hormonal Drug in Patients with Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations (PROfound): An Open-Label, Randomised, Phase 3 Trial","volume":"23","author":"Hussain","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.21.00941","article-title":"Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP","volume":"40","author":"Stockler","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1016\/S1470-2045(25)00520-0","article-title":"SISAQOL-IMI Consensus-Based Guidelines to Design, Analyse, Interpret, and Present Patient-Reported Outcomes in Cancer Clinical Trials","volume":"26","author":"Amdal","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_122","first-page":"EVIDra2400340","article-title":"Reading and Interpreting Quality-of-Life Results in Cancer Trials","volume":"4","year":"2025","journal-title":"NEJM Evid."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2017.75.3335","article-title":"Quality of Life During Treatment with Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer","volume":"36","author":"Morgans","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"102413","DOI":"10.1016\/j.eclinm.2023.102413","article-title":"15 Years of Patient-Reported Outcomes in Clinical Trials Leading to GU Cancer Drug Approvals: A Systematic Review on the Quality of Data Reporting and Analysis","volume":"68","author":"Paravathaneni","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e200363","DOI":"10.1001\/jamanetworkopen.2020.0363","article-title":"Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5489\/cuaj.6912","article-title":"Psychological Morbidity Associated with Prostate Cancer: Rates and Predictors of Depression in the RADICAL PC Study","volume":"15","author":"Fervaha","year":"2020","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41391-020-00286-0","article-title":"Depression, Anxiety, and Suicidality in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis of Observational Studies","volume":"24","author":"Brunckhorst","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2015.64.1969","article-title":"Association of Androgen Deprivation Therapy with Depression in Localized Prostate Cancer","volume":"34","author":"Dinh","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/pros.24676","article-title":"Development of Depression in Patients Using Androgen Deprivation Therapy: A Systemic Review and Meta-Analysis","volume":"84","author":"Qazi","year":"2024","journal-title":"Prostate"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/oncolo\/oyab033","article-title":"Depression, Anxiety, and Patterns of Mental Health Care Among Men with Prostate Cancer Receiving Androgen Deprivation Therapy","volume":"27","author":"Tsao","year":"2022","journal-title":"Oncologist"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e2200154","DOI":"10.1200\/GO.22.00154","article-title":"IRONMAN: A Novel International Registry of Men with Advanced Prostate Cancer","volume":"8","author":"Mucci","year":"2022","journal-title":"JCO Glob. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/s41391-021-00342-3","article-title":"The Effectiveness of Psychological Intervention for Depression, Anxiety, and Distress in Prostate Cancer: A Systematic Review of Literature","volume":"24","author":"Mundle","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2016.68.8788","article-title":"Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial","volume":"35","author":"Chambers","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s12529-019-09839-7","article-title":"Technology-Based Psychosocial Intervention to Improve Quality of Life and Reduce Symptom Burden in Men with Advanced Prostate Cancer: Results from a Randomized Controlled Trial","volume":"27","author":"Penedo","year":"2020","journal-title":"Int. J. Behav. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12529-024-10270-w","article-title":"Low Social Well-Being in Advanced and Metastatic Prostate Cancer: Effects of a Randomized Controlled Trial of Cognitive Behavioral Stress Management","volume":"32","author":"Gong","year":"2025","journal-title":"Int. J. Behav. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1470-2045(18)30060-3","article-title":"Effect of Early and Systematic Integration of Palliative Care in Patients with Advanced Cancer: A Randomised Controlled Trial","volume":"19","author":"Vanbutsele","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1016\/j.pec.2022.07.008","article-title":"Peer Support Interventions on Quality of Life, Depression, Anxiety, and Self-Efficacy among Patients with Cancer: A Systematic Review and Meta-Analysis","volume":"105","author":"Zhang","year":"2022","journal-title":"Patient Educ. Couns."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus Continuous Androgen Deprivation in Prostate Cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, Rapid, and Durable Prostate-Specific Antigen Decline with Apalutamide plus Androgen Deprivation Therapy Is Associated with Longer Survival and Improved Clinical Outcomes in TITAN Patients with Metastatic Castration-Sensitive Prostate Cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e258751","DOI":"10.1001\/jamanetworkopen.2025.8751","article-title":"Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial","volume":"8","author":"Azad","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1200\/JCO.2026.44.16_suppl.5004","article-title":"A Phase 2 Trial of Androgen Deprivation Therapy Interruption in Patients Responding Exceptionally to Androgen Receptor Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (A-DREAM\/Alliance A032101)","volume":"44","author":"Choudhury","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Grisay, G., Turco, F., Litiere, S., Fournier, B., Patrikidou, A., Gallardo, E., McDermott, R., Alanya, A., Gillessen, S., and Tombal, B. (2024). EORTC 2238 \u201cDe-Escalate\u201d: A Pragmatic Trial to Revisit Intermittent Androgen Deprivation Therapy in the Era of New Androgen Receptor Pathway Inhibitors. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1391825"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2465\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:14:57Z","timestamp":1785492897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":142,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152465"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152465","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]}}}